CClinicalTrials.gg
Status unknownNCT05583656Updated Oct 18, 2022

INSPIRIS RESILIA Valve in Pulmonary Position

An observational study in Pulmonary Valve Disorder and Congenital Heart Disease, sponsored by Medical University of Vienna. Status unknown at 1 site in Austria. Open to participants aged 5 Years to 99 Years. Per ClinicalTrials.gov, last updated 2022-10-18.

Sponsored by Medical University of Vienna · Observational

The sponsor has not verified this record recently (last verified Oct 2022), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
40
Ages
5 Years to 99 Years
Sex
All
01

Study summary

In this trial we intend to evaluate the safety and effectiveness of the INSPIRIS valve prothesis in the pulmonary position in patients of five years or older, with congenital or acquired pulmonary valve disease, requiring replacement of their native or prosthetic pulmonary valve.

Read the detailed description

Up to 40 subjects will be invited to participate in this trial after the indication for pulmonary valve replacement has been established. At the inclusion visit, patients will be screened according to the inclusion / exclusion criteria. After written informed consent, a detailed history will be obtained, and the study related exams will be performed.

The procedure will be performed through a median sternotomy with the help of cardiopulmonary bypass in a beating or arrested heart fashion depending on the individual surgeon's discretion. Any additional or residual defects will concomitantly be addressed. Either a native or prosthetic pulmonary valve will be replaced by an Edwards Inspiris valve (Edwards Lifesciences, Unterschleissheim, Germany). If a conduit is required, the valve will be sewn into a suitable prosthesis beforehand.

Subjects will be seen regularly after pulmonary valve implantation at hospital discharge, 6-month, 1 year and 2 years after surgery. A cardiac magnetic resonance imaging will be performed at inclusion and 2 years after surgery.

Total enrollment period for the study is estimated to be two years. The trial starts with the enrollment of the first patients and ends after the last patient enrolled has completed the two-year visit or has exited the study.

02

Conditions studied

  • Pulmonary Valve Disorder
  • Congenital Heart Disease
03

In context

Heart Diseases

3,639 studies on the registry are indexed under Heart Diseases; 461 are open to participants now.

This study's planned enrollment of 40 is below the median of 294 across 1,241 observational studies indexed under Heart Diseases.

Browse Heart Diseases studies →

Lead sponsor

Medical University of Vienna is the lead sponsor of 1,076 studies on the registry; 177 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of patients with pulmonary valve disease requiring pulmonary valve replacement of their native or prosthetic valve, equal to or greater than five years of age.

Inclusion criteria

  1. pulmonary valve disease requiring pulmonary valve replacement of their native or prosthetic valve, equal to or greater than five years of age.
  2. Patients and/or patient´s legal representatives must provide written informed consent as approved and required by the respective institutional review board and agree to its provisions.
  3. The patient has completed all preoperative investigations.

Exclusion criteria

Exclusion Criteria:

  1. Requires emergency surgery
  2. Has acute myocardial infarction (MI) within 30 days prior to screening date
  3. Has MRI or CT scan confirmed stroke, cerebrovascular accident (CVA) or transient ischemic attack (TIA) within six months prior to screening date
  4. Has hemodynamic or respiratory instability requiring inotropic support, mechanical circulatory support, or mechanical ventilation within 30 days prior to screening date
  5. Has active endocarditis/myocarditis or endocarditis/myocarditis within three months prior to screening date
  6. Has renal insufficiency as determined by creatinine level ≥ 2.5 mg/dL within 60 days prior to screening visit or end-stage renal disease
  7. Has documented:

    1. leukopenia (WBC \< 3.5x 103/µL),
    2. acute anemia (Hgb\<10.0 g/dL or 6 mmol/L), or
    3. thrombocytopenia (platelet count \< 50x 103/µL) accompanied by history of bleeding diathesis or coagulopathy within 60 days prior screening date
  1. Diagnosed with abnormal calcium metabolism and/or hyperparathyroidism 10. Echocardiographic evidence of an intra-cardiac mass, thrombus, or vegetation 11. RVOT aneurysm unless treated during pulmonary valve replacement surgery 12. Has prior organ transplant or is currently an organ transplant candidate 13. Was previously implanted with study trial device 14. Previously implanted with an aortic, mitral, or tricuspid bioprosthetic valve or mechanical valve 16. Has presence of non-cardiac disease limiting life expectancy to less than 12 months 17. Is currently or has recently participated (within six weeks) in another investigational drug or device trial 18. Positive urine or serum pregnancy test in female subjects of child-bearing potential and/or nursing mothers 20. Currently incarcerated or unable to give voluntary informed consent 21. Documented history of substance (drug or alcohol) abuse within the last five years prior to screening date
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No

Groups and cohorts

  • Edwards Inspiris Resilia Valve

    Procedure: Pulmonary valve replacement

Interventions

  • ProcedurePulmonary valve replacement

    Surgical replacement of the pulmonary valve using the Edwards Inspiris Resilia prosthesis.

06

What researchers measure

Primary outcomes

  1. Freedom from death and reoperation

    The primary safety endpoint for the trial is freedom from device or procedure related death and/or reoperation at 2 years after implantation.

    Time frame: 2 years after implantation

Secondary outcomes

  1. Safety endpoints

    all-cause mortality, structural valve deterioration, paravalvular leak, non-structural valve deterioration, transvalvular leak, trial valve-related mortality, endocarditis, valve thrombosis, explant and thromboembolism

    Time frame: 2 years after implantation

07

Study locations

1 of 1 sites recruiting
  • Medical University of Vienna
    Vienna, 1090, Austria
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05583656
Lead sponsor
Medical University of Vienna
Responsible party
Erhan Urganci (MD, Medical University of Vienna) — Principal investigator
First posted
Oct 18, 2022
Start date
Aug 12, 2019
Primary completion
Aug 1, 2023 (estimated)
Completion
Feb 1, 2024 (estimated)
Last update
Oct 18, 2022

Study contacts

Daniel Zimpfer, Prof. PD. Dr.
Contact
daniel.zimpfer@meduniwien.ac.at
+ 43 1 40400 56200

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion